High Grade NMIBC BCG Naive or post BCG- with or without CIS - Pfizer C6001001

Pfizer C6001001 Informed Consent Form

ClinicalTrials.gov

CURC Website

EBRT Candidates Prostate Cancer - Candel PrTK05

Radical Prostatectomy - Amgen Xaluritamig 237

Clinical trials are research studies involving people that test new ways to prevent, detect, or treat diseases. They are essential for advancing medical knowledge and finding better care options. Volunteers participate under careful medical supervision, with safety and ethical considerations paramount, and require informed consent.

Clinical Trial Basics

Locally Advanced/Metastatic UC - Genmab

mCRPC/mCSPC Post ARPI - Janssen KLK2 PASenger

mCSPC Treatment Naive or Post Taxane and/or ARPI Exposed- Novartis TulmiSTAR-02

Locally Advanced/Metastatic RCC - BMS ROSETTA RCC-208

Post ARPI in mCSPC or mCRPC- Fibrogen

Locally Advanced or Metastatic RCC - Pfizer Symbiotic-08

Men considered for radical prostatectomy typically have prostate cancer that is confined to the prostate (localized) and hasn't spread. The decision for surgery involves factors like cancer aggressiveness, your age, and overall health, aiming for a potential cure.

Radical Prostatectomy Candidates- Clarity CLARIFY

"Curium SOLAR-stage radical prostatectomy candidates" refers to men with prostate cancer whose condition is being assessed using specialized Curium SOLAR technology. This evaluation helps doctors determine if surgical removal of the prostate is the most appropriate and effective treatment for their specific cancer characteristics, guiding personalized care decisions.

Radical Prostatectomy Candidates- Curium SOLAR-stage

Radical Prostatectomy Candidates- Alessa EP-001

Radical Prostatectomy Candidates-CellVax refers to men with prostate cancer who are being evaluated for surgical removal of the prostate gland. This procedure is considered when cancer characteristics, stage, and overall health suggest it's the best option for cure or disease control. The 'CellVax' designation identifies a specific group within this broader patient population.

Radical Prostatectomy Candidates- CellVax

Localized high-risk prostate cancer means the cancer is found only within the prostate gland, but has features that indicate it might grow more quickly. While serious, being localized means it hasn't spread to other body parts. Common treatment approaches often include surgery or radiation. Open discussion with your care team is essential to understand your options.

Localized High-Risk Prostate Cancer- AZ EvoPAR02

PSA Relapse/BCR- Clarity AMPLIFY

PSA relapse means your Prostate-Specific Antigen (PSA) blood levels are rising again after prostate cancer treatment, suggesting the cancer may have returned. While often asymptomatic early on, further evaluation helps guide options. Novartis PSMA-DC is a specific treatment strategy considered in this context, alongside ongoing lifestyle support.

PSA Relapse - Novartis PSMA-DC

**PSA Relapse (or biochemical recurrence)** means your PSA blood test level has risen after initial prostate cancer treatment, suggesting the cancer may be returning. It's often found before symptoms. Your care team will monitor this and discuss appropriate next steps, which may include further evaluation or treatment options, alongside supporting your overall well-being.

PSA Relapse - Bayer ARASTEP

**ADT Candidate - Debiopharm** is not a medical condition itself, but refers to a potential new medication or therapy being developed by the company Debiopharm. This development is focused on improving **Androgen Deprivation Therapy (ADT)**. ADT is a common treatment for certain conditions, primarily prostate cancer, aiming to reduce male hormones that can fuel cancer growth. New ADT candidates seek to enhance treatment effectiveness or reduce side effects for patients.

ADT Candidate - Debiopharm

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) means prostate cancer has spread beyond the prostate but still responds to treatments that lower male hormones. "Treatment Naive" indicates this is the first systemic therapy for the widespread disease. "AZ EvoPAR01" likely refers to a specific initial treatment approach, often involving Abiraterone, used or studied to manage the cancer. Lifestyle support for overall well-being is also important.

mCSPC Treatment Naive AZ EvoPAR01

mCSPC Treatment Naive - Novartis JSB462C

mCSPC Treatment Naive- Pfizer MEVPRO-3

Castration-sensitive prostate cancer (CSPC) responds to treatments that lower testosterone. Castration-resistant prostate cancer (CRPC) means the cancer continues to grow despite low testosterone. Symptoms can include urinary changes or bone pain. Treatment aims to manage cancer growth and improve quality of life, often supported by healthy lifestyle choices.

CSPC or CRPC - Astellas ASP5541

Treatment Naive or Post-treatment mCSPC or mCRPC - AstraZeneca D7270C00001 ANDROMEDA

Metastatic Castration-Resistant Prostate Cancer (mCRPC) that is 'treatment naive' means prostate cancer has spread beyond the prostate and is growing despite hormone-lowering treatments, and this is its first systemic treatment for this advanced stage. Common symptoms might include bone pain or fatigue. Management focuses on controlling the disease, easing symptoms, and supporting overall well-being with various therapies.

mCRPC Treatment Naive - Pfizer 1003 MEVPRO-2

Metastatic Castration-Sensitive Prostate Cancer (mCSPC), Treatment Naive, describes prostate cancer that has spread beyond the prostate but still responds to hormone-lowering treatments. "Treatment naive" indicates this advanced cancer has not yet received systemic therapy. Symptoms can include bone pain or fatigue; treatment aims to control the cancer with hormone therapy and other medications, supported by a healthy lifestyle for overall well-being.

mCSPC Treatment Naive- Ambrx APEX-01

Metastatic Castration-Resistant Prostate Cancer (mCRPC) is advanced prostate cancer that has spread and continues to grow despite hormone therapy. Treatment aims to manage symptoms, which can include bone pain or fatigue, and extend life. Approaches like immunotherapy, such as Provenge, and other therapies are available, often alongside lifestyle adjustments to support well-being.

mCRPC - Dendreon ProvOne

This refers to prostate cancer that has spread (metastatic) and continues to grow despite hormone therapy (castration-resistant), even after treatment with medications like abiraterone. While symptoms vary (e.g., pain, fatigue), care focuses on managing the disease's spread and exploring advanced treatment options, including those through research, to improve well-being.

mCRPC Post Abi - Pfizer 1014 MEVPRO-1

This describes advanced prostate cancer that has spread (metastatic) and continues to grow despite standard hormone treatments, including newer hormone-blocking drugs (ARPIs). Patients in this situation may experience symptoms like pain or fatigue. Managing these symptoms and exploring advanced therapies for disease control are key focuses to maintain quality of life and well-being.

mCRPC Post ARPI - BMS rechARge

Post ARPI om mCSPC or mCRPC - Novartis AcTFirst

mCRPC Post ARPI- K36 STRIKE

This describes advanced prostate cancer that has spread (metastatic) and grown resistant to hormone therapy, specifically after treatment with powerful androgen receptor pathway inhibitors (ARPIs). Patients may experience varying symptoms like pain or fatigue, depending on where the cancer is. Management focuses on controlling symptoms, improving quality of life, and exploring new treatment options to best manage the disease.

mCRPC Post ARPI - Ambrx APEX-01

"mCRPC Post-ARPI" describes prostate cancer that has spread (metastatic) and is no longer controlled by hormone therapies, including advanced androgen-receptor pathway inhibitors. Symptoms may include bone pain, fatigue, or weight loss. For this advanced stage, your care team explores further treatment options to manage the disease and maintain your quality of life. Open communication with your doctors and focusing on overall well-being are key.

mCRPC Post-ARPI - Halda HLD-0915

mCRPC Post ARPI - GSK223054 EMBOLD

mCRPC- Post ARPI in mCSPC or mCRPC- AZ SEACLIFF

Post ARPI in mCSPC or mCRPC - Roche CO45813 InavoPC

Post ARPI in mCSPC or mCRPC - Daiichi Sankyo DS3201-343

mCRPC means advanced prostate cancer that has spread and is growing despite hormone treatment. Being an Olaparib candidate suggests your cancer has specific genetic changes, making it potentially responsive to this targeted oral medication. This approach aims to control cancer growth and manage symptoms, with supportive care vital for well-being.

mCRPC Olaparib Candidate - MOMA

mCRPC Post ARPI - Acerand

mCRPC (metastatic Castration-Resistant Prostate Cancer) means prostate cancer that has spread and continues to grow despite hormone therapy. While symptoms vary, care focuses on managing the disease and improving quality of life. Treatment options and lifestyle support are tailored, often including exploring new therapies.

mCRPC - EMD Serano M1774

mCRPC Post Taxane and Lu177- Janssen KLK2-comPAS

Low Grade Upper Tract Urothelial Carcinoma (UTUC) refers to a slow-growing cancer in the lining of your kidney or ureter. Symptoms can include blood in urine or flank pain. Risk factors include smoking. This condition is often managed with minimally invasive approaches, such as specific light-activated therapies (e.g., with the Steba TOOKAD ENLIGHTENED system), aimed at preserving kidney function.

Low Grade Upper Tract UC - Steba TOOKAD ENLIGHTENED

Low Grade Upper Tract UC - Urogen UT002

Low or Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC), sometimes classified using specific risk assessments like 'ErdaRIS', means cancer is found only in the bladder's inner lining without spreading to the muscle. Key symptoms can include blood in urine. Treatment often involves tumor removal and medication instilled into the bladder, with ongoing monitoring to prevent recurrence and maintain bladder health.

Low or Intermediate Risk NMIBC - ErdaRIS

Non-Muscle-Invasive Bladder Cancer (NMIBC) means cancer is in the bladder's inner lining, not deep muscle. Symptoms include blood in urine or frequent urges, often linked to smoking or chemical exposures. Treatment depends on cancer grade (low to high) and prior therapies like BCG, often involving surgery and additional treatments. Healthy lifestyle choices support overall well-being.

Low Grade or IR or High Grade NMIBC BCG Naïve or post BCG - AURA

Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC) is cancer found only in the bladder's inner lining, not deep into the muscle. This type has a moderate chance of recurrence. Symptoms often include blood in urine. Treatment usually involves surgery, sometimes followed by liquid medications placed directly into the bladder, with lifestyle adjustments like quitting smoking enhancing outcomes.

Intermediate Risk NMIBC - MoonRISe-1

Low or Intermediate Risk NMIBC - TYRA

Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC) is a type of bladder cancer found in the bladder's inner lining that has not spread to deeper muscle. This condition, sometimes encountered in specific clinical settings (e.g., 'Ferring ABLE-32'), can cause symptoms like blood in urine. Treatments typically involve removing the tumor and follow-up care. Quitting smoking significantly improves outcomes.

IR NMIBC - Ferring ABLE-32

High Grade NMIBC BCG Naive or post-BCG - Merck 3120-003

High-grade non-muscle invasive bladder cancer (NMIBC) means aggressive abnormal cells are found only in the bladder's inner lining, not the muscle. Symptoms can include blood in urine. Often linked to smoking, treatment involves removing the tumor. Further options, like medicines placed in the bladder or additional surgery, are considered, especially if prior therapies like BCG were not used or weren't effective.

High Grade NMIBC BCG Naïve or post BCG - SURGEtx

High Grade NMIBC BCG Naive or post BCG - Janssen MoonRISe-3

High-grade non-muscle invasive bladder cancer (NMIBC) is an aggressive cancer found only in the bladder's inner lining, not yet in the muscle. Symptoms can include blood in the urine. When standard treatments like BCG immunotherapy are not an option or if the cancer returns, specialized care focuses on preventing recurrence and progression.

High Grade NMIBC BCG Naïve or post BCG - Protara ADVANCED-2

"High Grade NMIBC post BCG - Theralase" describes an aggressive bladder cancer, located only in the bladder lining, which has recurred after prior immunotherapy (BCG). This context implies a need for advanced, often laser-based, treatments. Symptoms may include blood in urine or frequent urination. Management focuses on targeted therapies and close surveillance to prevent progression.

High Grade NMIBC post BCG w/ CIS - THERALASE

High Grade NMIBC post BCG w/ or w/o CIS - ImmVira

High-Grade Non-Muscle Invasive Bladder Cancer with Carcinoma In Situ (CIS) means aggressive cancer cells are found only in the inner lining of your bladder, not yet in the muscle. This condition has returned or persisted despite prior BCG treatment, indicating a need for alternative therapies. Symptoms can include blood in urine. Management focuses on removing cancerous tissue and exploring other treatments to prevent spread or recurrence, as this form can be persistent.

HG NMIBC post BCG w/ CIS - Ferring ABLE-22

High-grade non-muscle invasive bladder cancer (NMIBC) is an aggressive cancer in the bladder's inner lining, not muscle. The main symptom is blood in urine; smoking is a major cause. Initial treatment often involves surgery and bladder-instilled medication like BCG. This condition describes patients who haven't had BCG or whose cancer returned after it. Quitting smoking is crucial for management.

High Grade NMIBC Post BCG w/ or w/o CIS - enGene LEGEND

Locally Advanced or Metastatic Urothelial Carcinoma (UC) is bladder cancer that has spread to nearby tissues or distant organs. Symptoms can include blood in urine, pain, or fatigue. Management focuses on controlling the disease and improving quality of life, often supported by a healthy lifestyle.

Locally Advanced or Metastatic UC - Bicycle

Locally advanced or metastatic urothelial carcinoma (UC) means cancer of the bladder or urinary tract lining has spread significantly or to distant sites. Some cases have specific genetic changes, like an FGFR3 alteration, which can influence treatment. Symptoms may include blood in urine or pain. Treatment approaches are personalized and may include targeted therapies, chemotherapy, or immunotherapy, along with supportive care focusing on quality of life.

Locally Advanced or Metastatic UC - Eli Lilly FORAGER LOXO

Locally advanced or metastatic urothelial carcinoma (UC) is a type of cancer originating in the urinary tract lining, such as the bladder, that has spread beyond its initial site to nearby areas or distant organs. Symptoms can include blood in urine or pain, and smoking is a key risk factor. Treatment involves various therapies, like chemotherapy, immunotherapy, or targeted drugs, often alongside supportive care and healthy lifestyle choices.

Locally Advanced or Metastatic UC- Biohaven

Locally Advanced or Metastatic UC- AVENZO  AVZ-103-1001

Locally Advanced or Metastatic UC - GSK223054 EMBOLD

Locally Advanced or Metastatic UC - Rondo Therapeutics  RNDO-564-001

Locally Advanced or Metastatic UC - Daiichi Sankyo Tropion TU03

Locally Advanced or Metastatic RCC - Neopmorph NEO-811-101

Carolina Urologic Research Center

Office

Surgery (Urology)

Conditions that don't fit into other main groups. A mixed collection of health issues.

Other

Everyday health, wellness tips, and understanding how to manage your care.

General Health & Patient Education

Medical procedures are planned steps healthcare professionals take to diagnose, treat, or manage various health conditions. These can include diagnostic tests like imaging, therapeutic interventions, or surgical operations, all aimed at improving your health.

Procedures

Conditions that doctors fix, remove, or repair using an operation.

Common Surgical Procedures

Health issues treated by operations and care for healing.

Surgical and Post-Surgical Care

Cancers that start in the prostate gland, a male reproductive organ.

Prostate Cancer

Prostate problems that affect men's urination and health.

Prostate Conditions

Conditions affecting male organs, fertility, and sexual health.

Men's Reproductive Health

Diseases where body cells grow abnormally and can spread.

Cancer

Cancer conditions affecting the bladder, the organ storing urine.

Bladder cancer

Conditions affecting your kidneys and the tubes that carry urine.

Kidney & Ureter Conditions

Conditions affecting your bladder, kidneys, and how you urinate.

Carolina Urologic Research Center

High Grade NMIBC BCG Naive or post BCG- with or without CIS - Pfizer C6001001

Recommended Resources

Related Resources from Carolina Urologic Research Center

Meet Carolina Urologic Research Center

Locations

Find me online